Unusual Volume

Stitch Fix Shares Plunge 19% After Weak FY2027 Revenue and EBITDA Guidance

Read this in the Market Flux app

Stitch Fix, Inc. $SFIX

$2.20-21.99%as of publication

5D Change
-24.40%
Volume
37
vs Average
18.5Γ—
Market Cap
$398.94M

Stitch Fix tumbled roughly 19% in premarket trading on September 24, 2026, after the online personal styling company posted mixed fourth-quarter 2026 results and issued a fiscal 2027 outlook that badly missed Wall Street expectations. The company projected full-year FY2027 revenue of $1.31 billion to $1.36 billion, below analyst consensus, while also guiding for adjusted EBITDA margin compression that analysts called far weaker than anticipated. Management cited soft consumer spending and rising client acquisition costs as the primary headwinds weighing on the year ahead, undermining a recovery narrative that had attracted bullish investors.

The earnings release triggered a swift wave of analyst action. William Blair downgraded Stitch Fix to Market Perform from Outperform, citing customer growth concerns. Mizuho reiterated its Underperform rating, pointing directly to the guidance miss. Telsey Advisory Group kept its Market Perform rating but slashed its price target to $3 from $5. A Seeking Alpha analyst downgraded the stock to Sell, arguing that expected demand decay and EBITDA compression mean the company no longer qualifies as a high-quality holding in a volatile, rising-yield environment.

Β© AI-generated summary is provided by Market Flux

Sources

  1. InvestingStitch Fix Inc (SFIX) (Q4 2026) Earnings Call Highlights: Record Client Spend and Margin Gains ...
  2. seekingalpha.comStitch Fix, Inc. (SFIX) Q4 2026 Earnings Call Transcript
  3. Seeking AlphaStitch Fix projects FY 2027 revenue of $1.31B-$1.36B amid higher client acquisition costs
  4. benzinga.comStitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
  5. Marketsday#Pre-Market Buzz: Critical Updates Across Tech, AI Infrastructure, Mining, and Consumer Frontliners September 24, 2026 πŸ”Ή ACADIA Pharmaceuticals Focus: ACADIA Pharmaceuticals $ACAD saw active premarket turnover following pipeline updates for its central nervous system therapeutic programs. πŸ”Ή Viking Therapeutics Momentum: Viking Therapeutics $VKTX traded with heightened volume as clinical trial milestones for its metabolic and anti-obesity drug portfolio remain in sharp focus. πŸ”Ή MGM Resorts Travel Trends: MGM Resorts $MGM saw selective premarket activity tied to Las Vegas strip occupancy metrics and expanding digital gaming gross revenue figures. πŸ”Ή Stitch Fix Reorganization: Stitch Fix $SFIX remained in focus as market participants monitor ongoing margin improvement initiatives and client retention execution. #PreMarket #WallStreet #USMarkets #TechStocks #AIInfrastructure #Mining #EquityUpdate #MarketTrends
  6. investopedia.comStitch Fix Stock Dives on Soft Outlook
  7. ZerohedgePremarket movers Magnificent Seven: Alphabet (GOOGL) -0.7%, Amazon (AMZN) -0.9%, Apple (AAPL) unchanged, Microsoft (MSFT) -0.6%, Tesla (TSLA) -1%, Nvidia (NVDA) -1.1%, Meta Platforms (META) -2% Darden (DRI) falls 5% after the restaurant-chain operator posted first quarter sales that disappointed. Dropbox (DBX) declines 5% after Citi downgraded the file management software company to sell, writing that recent optimism about its AI strategy β€œderives too much success too early.” Etsy Inc. (ETSY) slips 2% after Arete downgraded the online retail platform to neutral, citing concerns over its valuation and growth sustainability. Everpure (P) jumps 7% after the data-storage company forecast revenue for 2028 that exceeded the average analyst estimate. MGM Resorts International (MGM) is down 9% after Barry Diller’s People Inc. dropped plans to acquire the rest of the casino giant. Stitch Fix (SFIX) falls 19% after the online personal styling platform forecast a much weaker full-year 2027 Ebitda that analysts expected. Viking Therapeutics (VKTX), which had surged 36% Tuesday on experimental weight-loss drug results, is down 12% after offering $200 million in common shares and another $200 million in convertible notes to help fund clinical development.
  8. OpenOutcrier$SFIX (-17.4% pre) Stitch Fix sees soft consumer spending weighing on FY27 sales
Show 2 more
  1. NasdaqStitch Fix (SFIX) Q4 2026 Earnings Call Transcript
  2. MarketRebelsStocks expected to have increasing option volume: $MGM $P $VKTX $COST $SFIX $DRI $BB